Definitive Healthcare (DH) Q2 2024 earnings summary

Executive summary

• Q2 2024 revenue grew 5% year-over-year to $63.7 million, with adjusted EBITDA up 21% to $20.9 million (33% margin), both above guidance, reflecting operational efficiency and profitability focus.

• Net loss widened to $306.2 million in Q2 2024, primarily due to a $363.6 million non-cash goodwill impairment charge.

• Enterprise customer base increased by 32 (6%) year-over-year to 537, while total customer count declined to approximately 2,600 due to higher churn among smaller customers.

• CEO transition completed, with Kevin Coop outlining a focus on operational simplification, platform unification, and direct sales oversight.

• Macroeconomic headwinds and sales execution challenges led to disruptions in sales and increased customer churn, especially among smaller customers.

Financial highlights

• Revenue: $63.7 million in Q2 2024, up 5% year-over-year; adjusted EBITDA: $20.9 million (33% margin), up 21%; adjusted net income: $14.2 million ($0.09 per diluted share).

• Net loss: $(306.2) million in Q2 2024, compared to $(11.6) million in Q2 2023, driven by goodwill impairment.

• Adjusted gross margin: 83% in Q2 2024, down 260 basis points year-over-year, mainly due to acquisitions.

• Unlevered free cash flow: $21.5 million in Q2 2024, $78.6 million TTM (up 50% year-over-year).

• Cash and equivalents: $120.9 million; short-term investments: $175.6 million as of June 30, 2024.

Outlook and guidance

• Q3 2024 revenue expected at $61.0–$62.5 million (down 4–7% year-over-year); adjusted EBITDA margin of 28–31%.

• Full-year 2024 revenue guidance: $247–$251 million (flat to down 2% year-over-year); adjusted EBITDA: $74–$77 million (30–31% margin).

• Margin expansion of 50–100 basis points expected for the full year despite top-line pressures.

• Adjusted net income for 2024 projected at $50–$53 million; adjusted EPS $0.32–$0.34.